GOSS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GO

Mkt Cap

$53.5M

Volume

158.35K

Next Earnings

November 4th

Loading chart

GO

GOSSGossamer Bio, Inc. Common Stock

GOSS

Pay with—

Available Balance0.00

GO

Mkt Cap

$54.4M

Volume

158.35K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightOver 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.GlobeNewswire Inc. · Sep 16, 2026

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is seeking investors who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its Phase 3 PROSERA study design, specifically concealing adverse facts about placebo response controls at certain testing sites.GlobeNewswire Inc. · May 31, 2026

GOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSSA securities class action lawsuit has been filed against Gossamer Bio (GOSS) alleging executives concealed placebo response risks in the Phase 3 PROSERA trial for seralutinib. The trial failed to meet its primary endpoint on February 23, 2026, causing an 80% stock price decline. The complaint claims management misled investors about trial design and patient recruitment despite knowing of significant placebo effects, particularly at Latin American sites.GlobeNewswire Inc. · May 31, 2026

GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSSRosen Law Firm has issued deadline notices for securities class action lawsuits against Gossamer Bio, Upstart Holdings, and POET Technologies. Investors with losses exceeding $100K are encouraged to secure counsel before upcoming deadlines. The lawsuits allege false and misleading statements regarding clinical trial design and other material facts.GlobeNewswire Inc. · May 30, 2026

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSSGossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price drop. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.GlobeNewswire Inc. · May 29, 2026

GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1stA class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) for allegedly providing materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The company is accused of expressing confidence in the trial design while concealing adverse facts about placebo response controls at Latin American testing sites, causing investors to purchase securities at artificially inflated prices. Investors who purchased shares between June 16, 2025, and February 20, 2026, have until June 1, 2026, to apply as lead plaintiff.GlobeNewswire Inc. · May 29, 2026

GOSSAMER DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSSRosen Law Firm is notifying investors in Gossamer Bio, Inc., FS KKR Capital Corp., and Regencell Bioscience Holdings Limited of ongoing securities class action lawsuits. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the June 1, 2026 deadline. The Gossamer case alleges defendants made false statements about their Phase 3 PROSERA study design while concealing material adverse facts.GlobeNewswire Inc. · May 28, 2026

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSSGossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price drop. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showing outsized placebo responses that compressed treatment efficacy.GlobeNewswire Inc. · May 27, 2026

Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Gossamer Bio, Inc. alleging that the company made materially false and misleading statements regarding its Phase 3 PROSERA study results while concealing material adverse facts about the study design, particularly regarding placebo response control at Latin American testing sites. The lawsuit covers investors who purchased Gossamer securities between June 16, 2025 and February 20, 2026.GlobeNewswire Inc. · May 25, 2026

GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSSRosen Law Firm is encouraging investors who purchased securities in Gossamer Bio, Upstart Holdings, and FS KKR Capital Corp. during specified periods to join class action lawsuits. The firm is seeking a lead plaintiff for the Gossamer case by June 1, 2026, with allegations involving false statements regarding a Phase 3 clinical study.GlobeNewswire Inc. · May 24, 2026

to start trading

GO

GOSSGossamer Bio, Inc. Common Stock

GOSS

Pay with—

Available Balance0.00

Your PositionYou don't own any GOSS yet.

Related Tickers

Earnings